Author: jb

Read original article on New African UK-based pharmaceutical company Stablepharma is preparing for a pivotal Phase 2b clinical trial of ‘SPVX02’, its thermostable version of an existing tetanus-diphtheria vaccine, following the success of a Phase 1 clinical trial. Unlike conventional vaccines which become unusable after a few hours or days out of the fridge, ‘SPVX02’ […]

Read original article on BMJ.com A tetanus-diphtheria vaccine that can be stored at room temperature has shown promising early results in a development hailed as a potential “game changer” for global health. Maintaining the cold chain for vaccines is a significant challenge in resource poor countries, remote communities, and regions affected by conflict. About half […]

Read original article on bbc.co.uk Vaccines that do not need to be kept cool in a fridge have been successfully trialled in patients for the first time, say UK scientists. Currently, most vaccines need to be refrigerated or frozen – but around half are wasted each year, mainly because they become unusable after getting too […]

click here to read full article

Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by Professor Saul Faust, is being conducted at the National Institute for Health and Care Research (NIHR) at Southampton Clinical Research Facility. Stablepharma’s pioneering science has […]

click here to read full article

Researchers at University Hospital Southampton (UHS) are working with Stablepharma Ltd to trial vaccines that don’t need to be kept cold. The partners have been awarded a joint grant by Innovate UK to develop a fridge-free vaccine, SPVX02, to prevent tetanus and diphtheria.